Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT06227897
What this trial is testing

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Who this might be right for
Lung Cancer
Sun Yat-sen University
Early research (Phase 1)WithdrawnNCT01836341
What this trial is testing

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Who this might be right for
Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197008
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

Who this might be right for
Lung Cancer
Li-kun Chen 50
Testing effectiveness (Phase 2)Looking for participantsNCT06863506
What this trial is testing

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Second Affiliated Hospital, Zhejiang University, School of Medicine 78
Not applicableLooking for participantsNCT07143045
What this trial is testing

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Who this might be right for
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 800
Not applicableUnknownNCT02851329
What this trial is testing

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

Who this might be right for
Non-small Cell Lung Cancer
Chinese Academy of Sciences 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07413952
What this trial is testing

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 45
Not applicableUnknownNCT04304638
What this trial is testing

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III Non-small-cell Lung CancerEGFR Mutation-Related Tumors
Chinese Academy of Medical Sciences 450
Testing effectiveness (Phase 2)Looking for participantsNCT06355609
What this trial is testing

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Not applicableUnknownNCT03916913
What this trial is testing

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Chinese Academy of Medical Sciences 85
Testing effectiveness (Phase 2)Looking for participantsNCT04410796
What this trial is testing

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 571
Not applicableUnknownNCT04944069
What this trial is testing

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Who this might be right for
NSCLCLeptomeningeal MetastasisEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 69
Testing effectiveness (Phase 2)UnknownNCT05244213
What this trial is testing

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

Who this might be right for
Non-small Cell Lung CancerEGFR Activating Mutation
Guangdong Provincial People's Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT07742332
What this trial is testing

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Who this might be right for
EGFRNSCLC (Non-small Cell Lung Cancer)Locally Advanced Non-Small Cell Lung Cancer+2 more
Peng Zhang 160
Testing effectiveness (Phase 2)Ended earlyNCT01189435
What this trial is testing

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 2
Early research (Phase 1)UnknownNCT02151721
What this trial is testing

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
Kanazawa University 12
Testing effectiveness (Phase 2)Looking for participantsNCT06652048
What this trial is testing

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Who this might be right for
Non-Small Cell Lung Cancer
Jialei Wang 60
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07177092
What this trial is testing

Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR
Jianxing He 118
Next Page